PDS Biotechnology to Host Conference Call Following Poster Presentations of PDS0101 Data at ASCO 2022 Annual Meeting

PDS Biotechnology Company

Conference call on Tuesday, June 7, 2022 at 8:00 a.m. EDT

FLORHAM PARK, NJ, May 25, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing portfolio of cancer immunotherapies and vaccines for targeted infectious diseases molecular, today announced that its leadership team will host a conference call following two poster presentations of PDS0101 data at the 2022 meeting of the American Society of Clinical Oncology (ASCO).

During the call, PDS Biotech will review data from both poster presentations:

  • Phase 2 clinical trial led by the National Cancer Institute (NCI), studying PDS0101 in combination with two investigational immunomodulatory agents for the treatment of advanced refractory HPV-associated cancers and;

  • VERSATILE-002 Phase 2 trial of PDS0101 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for treatment of recurrent or metastatic HPV16 positive head and neck cancer.

Following the presentation, PDS Biotech will hold a Q&A session. The call details are as follows:

Post-ASCO conference call
Date: Tuesday, June 7, 2022
Time: 8:00 a.m. EDT
Domestic: 877-407-3088
International: +1 201-389-0927
Conference ID: 13729901
Webcast: Webcast PDS Biotech Post ASCO

Following the conference call, a replay of the webcast will be available in the Investors section of the Company’s website, PDS Biotechnology.

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing portfolio of molecularly targeted immunotherapies for cancer and infectious diseases based on the company’s proprietary Versamune technology.® and Infectimune™ T cell activation technology platforms. We believe that our Versamune®Immunotherapy-based products demonstrate the potential to overcome the limitations of current immunotherapy by inducing live, large amounts of high quality and very potent polyfunctional CD4+ and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and attack and destroy them effectively. The Company continues to advance its pipeline of candidates to treat a wide range of diverse cancers, including HPV16-associated cancers (anal, cervical, head and neck, penis, vaginal, vulvar) and cancers of the breast, colon, lung, prostate and ovary.

To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Forward-looking statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) regarding PDS Biotechnology Corporation ( the “Company”) and other matters. These statements may discuss objectives, intentions and expectations with respect to future plans, trends, events, results of operations or financial condition, or otherwise, based on the current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend on or refer to future events or conditions, and include words such as “may”, “will”, “should”, “should”, “expect to”, “expect”, “plan”, “probable”, “believe”, “estimate”, “project”, “intend”, “plan”, “direction”, “prospects and other similar expressions, among others. Forward-looking statements are based on current beliefs and assumptions which are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement due to a variety of factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s expected capital requirements, including the Company’s expected cash flow and the Company’s current expectations regarding its future equity financing plans; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that the raising of such additional capital may restrict the Company’s operations or require the Company to waive any rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current industry, which makes it difficult to assess the Company’s prospects, the Company’s business plan or the likelihood of successful implementation of this business plan by the Company; the timing for the Company or its partners to initiate planned clinical trials for PDS0101, PDS0203 and other product candidates based on Versamune® and Infectimune™; the future success of these trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaborative study regarding PDS0101, PDS0203 and other Versamune ® and Infectimune™ based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and planned clinical trials for the Company’s current product candidates, including statements regarding timing of initiation, rate of recruitment and completion of trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes that no material changes will be made to our currently projected expenditures), futility analyses, presentations at conferences and data reported in a summary, and receipt of interim results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any statements by the Company regarding its understanding of the mechanisms of action of product candidates and the interpretation of preclinical and early clinical results from its clinical development programs and any collaborative studies; and other factors, including legislative, regulatory, political and economic developments that are not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations resulting from or related to COVID- 19. The above discussion of important factors that could cause actual events to differ from expectations should not be construed as complete and should be read in conjunction with the statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the latter. Forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statement, whether as a result of new information, future events or otherwise.

KEYTRUDA ® is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Versamune ® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology.

Investor contacts:
rich rooster
CG Capital
Phone: +1 (404) 736-3838
[email protected]

Michael P. Boser